New combo therapy targets hard-to-treat thyroid and salivary cancers
NCT ID NCT03360890
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 29 times
Summary
This phase 2 study tests whether adding the immunotherapy drug pembrolizumab to the chemotherapy drug docetaxel can shrink tumors in people with advanced thyroid or salivary gland cancers that are not responding to standard treatments. About 46 adults with these rare, hard-to-treat cancers will receive both drugs every three weeks. The main goal is to see how many patients have their tumors shrink or disappear.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYROID CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Chicago Comprehensive Cancer Center
Chicago, Illinois, 60637, United States
Conditions
Explore the condition pages connected to this study.